

## Special Issue

# Novel Cell Death Mechanism: Pioneering New Avenues in Cancer Therapy

### Message from the Guest Editor

Dysregulation of cell death is a hallmark of cancer, contributing to tumor progression, metastasis, and therapeutic resistance. In recent years, novel forms of nonapoptotic cell death, including ferroptosis, pyroptosis, necroptosis, cuproptosis, and entosis, have emerged as critical regulators in both solid tumors and hematological malignancies. This Special Issue focuses on the latest advances in understanding novel cell death mechanisms and their translational potential in cancer therapy, including the role of fecal microbiota transplantation (FMT), which has shown promising potential in modulating the tumor microenvironment and overcoming therapeutic resistance, especially in hematological malignancies. We welcome original research articles, reviews, and communications that explore the molecular regulation of unconventional cell death pathways, their crosstalk with the tumor microenvironment and FMT-related mechanisms, and strategies to target these processes for developing anticancer drugs, combination therapies, and precision medicine.

---

### Guest Editor

Dr. Xiaobo Wang

Department of Hematology, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen 518106, China

---

### Deadline for manuscript submissions

31 December 2026



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/280975](https://mdpi.com/si/280975)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).